Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man's Trash Is Another Man's Treasure

Urinary bladder cancer (UBC) is the most common malignancy of the urinary tract in humans, with an estimated global prevalence of 1.1 million cases over 5 years. Because of its high rates of recurrence and resistance to chemotherapy, UBC is one of the most expensive cancers to treat, resulting in si...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 3; p. 422
Main Authors Minkler, Sarah, Lucien, Fabrice, Kimber, Michael J, Sahoo, Dipak K, Bourgois-Mochel, Agnes, Musser, Margaret, Johannes, Chad, Frank, Igor, Cheville, John, Allenspach, Karin, Mochel, Jonathan P
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 23.01.2021
MDPI
Subjects
Biopsy
Bladder cancer
Cancer therapies
Chemotherapy
Clinical trials
Decision making
Drug testing
exosomes
Gene expression
Histology
Immunotherapy
Malignancy
Management decisions
one health
organoids
Patients
Phenotypes
Precision medicine
Review
Surgery
Tumors
Urinary bladder
Urinary tract
Urine
Vesicles
precision medicine
one health
bladder cancer
exosomes
organoids
Online AccessGet full text

Cover

More Information
Summary:Urinary bladder cancer (UBC) is the most common malignancy of the urinary tract in humans, with an estimated global prevalence of 1.1 million cases over 5 years. Because of its high rates of recurrence and resistance to chemotherapy, UBC is one of the most expensive cancers to treat, resulting in significant health care costs. The development of innovative molecular and cellular tools is necessary to refine patient stratification and help predict response to treatment. Urine is an underused resource of biological components shed from bladder tumors, such as exfoliated cells and extracellular vesicles, that could serve as molecular fingerprints and provide valuable biological insights into tumor phenotype and mechanisms of resistance to chemotherapy. Additionally, characterization of urine-derived extracellular vesicles and cells could be used as reliable biomarkers for prediction of response to neoadjuvant therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13030422